Literature DB >> 33811614

Dihydroxyeicosatrienoic Acid, a Metabolite of Epoxyeicosatrienoic Acids Upregulates Endothelial Nitric Oxide Synthase Expression Through Transcription: Mechanism of Vascular Endothelial Function Protection.

Deyu Zuo1, Qiangzhong Pi2, Yunmin Shi2, Suxin Luo2, Yong Xia3.   

Abstract

The present study aimed to investigate the impacts and underlying mechanisms of 14,15-DHETs on eNOS and vascular endothelial functions. Bovine aortic endothelial cells (BAECs) were treated with various concentrations of 14, 15-DHET. The expressions of eNOS protein and mRNA were observed at different time points. The eNOS expression and phosphorylation were subsequently detected administered with 8,9-DHET, 11,12-DHET, and 14,15-DHET, respectively. Meanwhile, 14,15-DHET action on tube formation was observed in human umbilical vein endothelial cells (HUVECs). Finally, the aorta of male C57BL/6 mice was injected with 14,15-DHET via the tail vein. The impacts of 14,15-DHET (0.4 mg/kg body weight) on the expressions of eNOS protein and mRNA and endothelium-dependent vasodilation (EDV) were detected following 24 h. The expression of eNOS was greatly improved with the 14,15-DHET treatment compared with the BAECs, and eNOS phosphorylation sites at Ser1179, Ser635, and Thr497 were elevated. However, no statistically significant difference was revealed on total eNOS among the 8,9-DHET, 11,12-DHET, and 14,15-DHET treatment groups. Based on the upregulation of eNOS protein, eNOS mRNA levels were increased in BAECs and thoracic aorta of the male C57BL/6 mice treated with 14,15-DHET, suggesting that transcriptional activation was achieved in vascular eNOS. Moreover, 14,15-DHET enhanced tube formation abilities in HUVECs and acetylcholine(ACh)-induced EDV. These findings indicated that 14,15-DHET could improve the vascular endothelial diastolic functions of male C57BL/6 mice, and enhance the ability of tube formation, which might be related to the increase of eNOS expression.

Entities:  

Keywords:  14,15-DHET; Endothelial function; HUVECs; Tube formation; eNOS

Year:  2021        PMID: 33811614     DOI: 10.1007/s12013-021-00978-x

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  30 in total

Review 1.  Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization.

Authors:  J L Boucher; C Moali; J P Tenu
Journal:  Cell Mol Life Sci       Date:  1999-07       Impact factor: 9.261

Review 2.  Epoxygenase pathways of arachidonic acid metabolism.

Authors:  D C Zeldin
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

Review 3.  What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle?

Authors:  F Murad
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

Review 4.  The role of nitric oxide in cardiovascular diseases.

Authors:  Khalid M Naseem
Journal:  Mol Aspects Med       Date:  2005-01-24

5.  The arachidonic acid effect on platelet nitric oxide level.

Authors:  Maria Grazia Signorello; Alessia Segantin; Giuliana Leoncini
Journal:  Biochim Biophys Acta       Date:  2009-07-14

6.  Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.

Authors:  Martin Spiecker; Harald Darius; Thomas Hankeln; Muhidien Soufi; Alexander M Sattler; Jürgen R Schaefer; Koichi Node; Jan Börgel; Andreas Mügge; Klaus Lindpaintner; Anika Huesing; Bernhard Maisch; Darryl C Zeldin; James K Liao
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

Review 7.  eNOS, metabolic syndrome and cardiovascular disease.

Authors:  Paul L Huang
Journal:  Trends Endocrinol Metab       Date:  2009-07-31       Impact factor: 12.015

Review 8.  Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice.

Authors:  Masato Tsutsui; Hiroaki Shimokawa; Yutaka Otsuji; Yoichi Ueta; Yasuyuki Sasaguri; Nobuyuki Yanagihara
Journal:  Circ J       Date:  2009-05-09       Impact factor: 2.993

9.  Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.

Authors:  John W Calvert; Susheel Gundewar; Saurabh Jha; James J M Greer; William H Bestermann; Rong Tian; David J Lefer
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

Review 10.  Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.

Authors:  Yangmei Deng; Katherine N Theken; Craig R Lee
Journal:  J Mol Cell Cardiol       Date:  2009-11-03       Impact factor: 5.000

View more
  2 in total

1.  Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice.

Authors:  Yan Gong; Yohei Tomita; Matthew L Edin; Anli Ren; Minji Ko; Jay Yang; Edward Bull; Darryl C Zeldin; Ann Hellström; Zhongjie Fu; Lois E H Smith
Journal:  Metabolism       Date:  2022-07-19       Impact factor: 13.934

2.  Oxylipin profile in saliva from patients with cystic fibrosis reveals a balance between pro-resolving and pro-inflammatory molecules.

Authors:  Vincenzo Carnovale; Alice Castaldo; Alessandro Di Minno; Monica Gelzo; Paola Iacotucci; Anna Illiano; Gabriella Pinto; Giuseppe Castaldo; Angela Amoresano
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.